Azad TD, Chaudhuri AA, Fang P, et al. - Since biomarkers are required to identify patients at risk of tumor progression following chemoradiotherapy for localized esophageal cancer, researchers conducted deep sequencing (CAPP-Seq) analyses of plasma cell-free DNA obtained from 45 individuals before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes, and fixed esophageal tumor biopsies gathered during esophagogastroduodenoscopy. According to findings, detection of ctDNA was linked to tumor progression, metastasis, and disease-specific survival in an analysis of cell-free DNA in blood samples from individuals who had chemoradiotherapy for esophageal cancer. CtDNA analysis may be used to identify patients at the highest risk of tumor progression.